Jinhua Wang

发表

A Landscape of Pharmacogenomic Interactions in Cancer

Emanuel J. V. Gonçalves, M. Stratton, G. Bignell, 2016, Cell.

Fluorescent Visualization of Src by Using Dasatinib‐BODIPY

Shuai Liu, Zijuan Zhang, N. Gray, 2014, Chembiochem : a European journal of chemical biology.

Extracellular signal–regulated kinase 5 promotes acute cellular and systemic inflammation

N. Gray, K. Wilhelmsen, Jinhua Wang, 2015, Science Signaling.

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

D. Sabatini, N. Gray, Qingsong Liu, 2010, Journal of medicinal chemistry.

Inhibition of the deubiquitinase USP10 induces degradation of SYK

N. Gray, Jinhua Wang, J. Griffin, 2020, British Journal of Cancer.

Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities.

S. Knapp, N. Gray, Yanke Liang, 2020, Cell chemical biology.

Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities

S. Knapp, N. Gray, Yanke Liang, 2020, bioRxiv.

Development of ATP-competitive mTOR inhibitors.

D. Sabatini, N. Gray, Qingsong Liu, 2012, Methods in molecular biology.

Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice

M. Sur, R. Jaenisch, N. Gray, 2019, Science Translational Medicine.

Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis

N. Gray, B. Telfer, Jinhua Wang, 2020, Cancer Research.

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification

T. Willson, Mathias Frederiksen, S. Knapp, 2019, bioRxiv.

Resource A Landscape of Pharmacogenomic Interactions in Cancer Graphical Abstract Highlights

Emanuel J. V. Gonçalves, M. Stratton, G. Bignell, 2016 .

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

N. Gray, Jinhua Wang, J. Griffin, 2020, Journal of cellular and molecular medicine.

Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.

P. Sorger, N. Gray, K. Westover, 2020, Cell chemical biology.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

N. Gray, Qingsong Liu, Xianming Deng, 2015, PloS one.

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

N. Gray, Qingsong Liu, W. Hur, 2017, European journal of medicinal chemistry.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies

N. Gray, Jinhua Wang, J. Griffin, 2019, British journal of haematology.

Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold.

Y. Liu, N. Gray, K. Westover, 2022, European journal of medicinal chemistry.

Generation of a chemical genetic model for JAK3

J. Reményi, N. Gray, Jinhua Wang, 2021, Scientific Reports.

Discovery of host‐targeted covalent inhibitors of dengue virus

N. Gray, Qingsong Liu, Yanke Liang, 2017, Antiviral research.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.

M. McKeown, Xiang Xu, Dennis L. Buckley, 2018, ACS chemical biology.

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas

N. Munshi, N. Gray, Jinhua Wang, 2022, Blood advances.

Synthesis and structure activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold.

Stephen J. Capuzzi, A. Tropsha, N. Gray, 2020, Journal of Medicinal Chemistry.

SIKs control osteocyte responses to parathyroid hormone

R. Xavier, R. Baron, M. Bouxsein, 2016, Nature Communications.

Corrigendum: SIKs control osteocyte responses to parathyroid hormone

R. Xavier, R. Baron, M. Bouxsein, 2017, Nature Communications.

SIKs control osteocyte responses to parathyroid hormone Citation

R. Xavier, R. Baron, M. Bouxsein, 2016 .

SnapShot: Kinase Inhibitors I.

N. Gray, Jinhua Wang, 2015, Molecular cell.

Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer

D. Sabatini, N. Gray, Qingsong Liu, 2011 .

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy

N. Gray, R. Davey, M. Słabicki, 2022, Journal of medical virology.

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

P. Jänne, N. Gray, Wenjun Zhou, 2012, Bioorganic & medicinal chemistry letters.

Prospects for Antibacterial Discovery and Development.

N. Gray, C. Walsh, C. Khosla, 2021, Journal of the American Chemical Society.

Functional kinomics establishes a critical node of volume-sensitive cation-Cl− cotransporter regulation in the mammalian brain

S. Elledge, Jinhua Wang, D. Alessi, 2016, Scientific Reports.

Doping evolution of superconductivity, charge order and band topology in hole-doped topological kagome superconductors Cs(V$_{1-x}$Ti$_x$)$_3$Sb$_5$

Jinhua Wang, Jianfeng Wang, Yongqing Cai, 2021, 2110.12651.

Discovery of a selective inhibitor of Doublecortin Like Kinase 1

Charles Y. Lin, W. Hahn, A. Look, 2020, Nature Chemical Biology.

Repurposing of Kinase Inhibitors for Treatment of COVID-19

N. Gray, A. Parent, Jinhua Wang, 2020, Pharmaceutical Research.

Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.

Jenifer B. Kaplan, N. Gray, S. Ficarro, 2018, Cell chemical biology.

mTOR Mediated Anti-Cancer Drug Discovery.

D. Sabatini, N. Gray, Qingsong Liu, 2009, Drug discovery today. Therapeutic strategies.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

S. Elledge, D. Sabatini, M. Niepel, 2013, Cancer research.

Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR Citation

S. Elledge, D. Sabatini, M. Niepel, 2013 .

ATM , and ATR Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

mTOR , ATM and ATR Characterization of Torin 2 , an ATP-competitive inhibitor of

S. Elledge, D. Sabatini, M. Niepel, 2013 .

Therapeutics , Targets , and Chemical Biology Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

Synergistic interactions with PI3K inhibition that induce apoptosis

John G Doench, W. Hahn, M. Cima, 2017, eLife.

Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.

N. Gray, Xianming Deng, T. Mitchison, 2012, ACS chemical biology.

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development

N. Gray, Yanke Liang, Jinhua Wang, 2020, Cell.

Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases

N. Gray, Wenjun Zhou, Xianming Deng, 2013, The Biochemical journal.

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

P. Jänne, N. Gray, Xianming Deng, 2011, ACS medicinal chemistry letters.

Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.

Mario Medvedovic, Eugen Lounkine, Marc Hafner, 2019, Cell chemical biology.

Cheminformatics tools for analyzing and designing optimized small molecule libraries

Mario Medvedovic, Eugen Lounkine, Marc Hafner, 2018, bioRxiv.

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

Charles Y. Lin, Mousheng Xu, J. Qi, 2018, eLife.

Targeting MYC dependency in ovarian cancer through inhibition of 1 CDK 7 and CDK 12 / 13 2

Charles Y. Lin, Mousheng Xu, J. Qi, 2022 .

Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective and orally available mTOR inhibitor for treatment of cancer

D. Sabatini, N. Gray, Qingsong Liu, 2011 .

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013 .

Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.

N. Gray, B. Telfer, Jinhua Wang, 2022, Cancer research communications.

ERK5 is activated by oncogenic BRAF and promotes melanoma growth

N. Gray, Xianming Deng, Jinhua Wang, 2018, Oncogene.

Identi ﬁ cation and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

J. Radich, N. Gray, Xianming Deng, 2022 .

Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

S. Knapp, N. Gray, Xianming Deng, 2013, European journal of medicinal chemistry.

GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein.

N. Gray, Jinhua Wang, Jianming Zhang, 2016, Cell chemical biology.

Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption

Daniel J. O'Connell, R. Xavier, M. Bouxsein, 2021, bioRxiv.

Chemical Interrogation of the Malaria Kinome

N. Gray, Wenjun Zhou, M. Mota, 2014, Chembiochem : a European journal of chemical biology.

Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.

K. Stegmaier, N. Gray, Jinhua Wang, 2019, Blood.

A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin

N. Gray, H. Choi, D. Fisher, 2017, Cell reports.

Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

M. Noble, N. Gray, S. Cook, 2020, Nature Communications.

Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2

A. Look, N. Gray, Jinhua Wang, 2020, Cell.

Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis

A. Burlingame, J. Trojanowski, E. Huang, 2016, Neuron.

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations

N. Gray, Jinhua Wang, J. Griffin, 2020, Journal of cellular and molecular medicine.

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

N. Munshi, N. Gray, Jinhua Wang, 2021, Blood.

Human Polo-like Kinase Inhibitors as Antiplasmodials.

Edward L. Huttlin, E. Winzeler, S. Gygi, 2023, ACS infectious diseases.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

N. Gray, Jinhua Wang, S. Treon, 2018, Blood.

BTK drives ibrutinib resistance via ERK1/2, and protects BTK MYD88 mutated cells by a paracrine mechanism

Amanda, N. Gray, Jinhua Wang, 2018 .

A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation

N. Gray, S. Whelan, Yanke Liang, 2019, The Journal of Biological Chemistry.

Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.

N. Gray, Qingsong Liu, Yanke Liang, 2017, ACS medicinal chemistry letters.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, OncoTarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

N. Gray, Jinhua Wang, J. Griffin, 2019, Leukemia.

Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition

N. Gray, B. Telfer, Jinhua Wang, 2018, Proceedings of the National Academy of Sciences.

Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation

N. Gray, Jinhua Wang, M. Geyer, 2021, Nature Communications.

Erk5 Is a Key Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity

N. Gray, Jinhua Wang, R. Toth, 2016, Cell reports.

Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

M. Noble, N. Gray, S. Cook, 2020, Nature Communications.

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

N. Gray, Jinhua Wang, S. Treon, 2020, Blood Cancer Journal.

Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics*

P. Sorger, D. Sabatini, A. Look, 2012, The Journal of Biological Chemistry.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.

N. Gray, Wenjun Zhou, Tinghu Zhang, 2018, Journal of medicinal chemistry.

Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.

N. Gray, Jinhua Wang, Priscilla L. Yang, 2019, ACS infectious diseases.

Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins

N. Gray, Xianming Deng, G. Wilkie, 2017, Antiviral research.

Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.

D. Sabatini, N. Gray, Qingsong Liu, 2011, Bioorganic & medicinal chemistry letters.

The Salt-Inducible Kinase inhibitor YKL-05-099 suppresses MEF2C function and acute myeloid leukemia progression in vivo

K. Stegmaier, N. Gray, Jinhua Wang, 2019, bioRxiv.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Identification of small molecule inhibitors targeting the Zika virus envelope protein.

N. Gray, Jinhua Wang, Priscilla L. Yang, 2019, Antiviral research.

Inhibition of the deubiquitinase USP10 induces degradation of SYK

N. Gray, Jinhua Wang, J. Griffin, 2020, British Journal of Cancer.

Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities

S. Knapp, N. Gray, Yanke Liang, 2020, bioRxiv.

Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.

N. Gray, Jinhua Wang, Priscilla L. Yang, 2018, ACS infectious diseases.

Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Christopher J. Ott, Charles Y. Lin, R. Young, 2018, Blood.

Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.

Nicholas A. Clark, Y. Wang, P. Sorger, 2019, Cell chemical biology.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.

N. Gray, Wenjun Zhou, Tinghu Zhang, 2018, Journal of medicinal chemistry.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

N. Gray, Qingsong Liu, W. Hur, 2013, ACS chemical biology.

Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases.

E. Winzeler, Jinhua Wang, Patrick K. Tumwebaze, 2024, Journal of medicinal chemistry.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases

N. Gray, Wenjun Zhou, Xianming Deng, 2013, The Biochemical journal.